HUP0302573A2 - Humanizált anti-LT-béta-R ellenanyagok - Google Patents

Humanizált anti-LT-béta-R ellenanyagok

Info

Publication number
HUP0302573A2
HUP0302573A2 HU0302573A HUP0302573A HUP0302573A2 HU P0302573 A2 HUP0302573 A2 HU P0302573A2 HU 0302573 A HU0302573 A HU 0302573A HU P0302573 A HUP0302573 A HU P0302573A HU P0302573 A2 HUP0302573 A2 HU P0302573A2
Authority
HU
Hungary
Prior art keywords
antibodies
humanized anti
betha
beta receptor
cancer diseases
Prior art date
Application number
HU0302573A
Other languages
English (en)
Inventor
Ellen A. Garber
Paul Lyne
Jose W. Saldanha
Original Assignee
Biogen, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen, Inc. filed Critical Biogen, Inc.
Publication of HUP0302573A2 publication Critical patent/HUP0302573A2/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

A találmány tárgyát általánosságban lymphotoxin béta receptor ellenispecifikus humanizált ellenanyagok (anti-LT-b-R) képezik. A találmánytárgyát közelebbről humanizált anti-lymphotoxin béta receptor (LT-b-R)ellenanyagok, valamint a találmány szerinti ellenanyagok daganatosmegbetegedések kezelésére és daganatos megbetegedésekelőrehaladásának, súlyosságának vagy hatásának mérséklésére történőalkalmazása képezi. Ó
HU0302573A 2000-10-13 2001-10-12 Humanizált anti-LT-béta-R ellenanyagok HUP0302573A2 (hu)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US24028500P 2000-10-13 2000-10-13
US27528901P 2001-03-13 2001-03-13
US29998701P 2001-06-21 2001-06-21
PCT/US2001/032140 WO2002030986A2 (en) 2000-10-13 2001-10-12 HUMANIZED ANTI-LT-β-R ANTIBODIES

Publications (1)

Publication Number Publication Date
HUP0302573A2 true HUP0302573A2 (hu) 2003-10-28

Family

ID=27399340

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0302573A HUP0302573A2 (hu) 2000-10-13 2001-10-12 Humanizált anti-LT-béta-R ellenanyagok

Country Status (25)

Country Link
US (2) US7429644B2 (hu)
EP (1) EP1326897A2 (hu)
JP (1) JP2004532608A (hu)
KR (1) KR20030041164A (hu)
CN (1) CN1547590A (hu)
AR (1) AR035352A1 (hu)
AU (2) AU2002211747B2 (hu)
BG (1) BG107802A (hu)
BR (1) BR0114646A (hu)
CA (1) CA2425809A1 (hu)
CZ (1) CZ20031307A3 (hu)
EA (1) EA006945B1 (hu)
EE (1) EE200300179A (hu)
GE (1) GEP20063752B (hu)
HU (1) HUP0302573A2 (hu)
IL (1) IL155340A0 (hu)
IS (1) IS6779A (hu)
MX (1) MXPA03003144A (hu)
NO (1) NO20031642L (hu)
NZ (1) NZ525793A (hu)
PL (1) PL366307A1 (hu)
SK (1) SK5672003A3 (hu)
TR (2) TR200300478T2 (hu)
WO (1) WO2002030986A2 (hu)
YU (1) YU28503A (hu)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
US5925351A (en) 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
NZ544924A (en) 2003-06-27 2009-03-31 Biogen Idec Inc Modified binding molecules comprising connecting peptides
WO2005047327A2 (en) 2003-11-12 2005-05-26 Biogen Idec Ma Inc. NEONATAL Fc RECEPTOR (FcRn)-BINDING POLYPEPTIDE VARIANTS, DIMERIC Fc BINDING PROTEINS AND METHODS RELATED THERETO
KR20060132006A (ko) * 2004-03-23 2006-12-20 비오겐 아이덱 엠에이 아이엔씨. 수용체 커플링제 및 이의 치료적 용도
US8153123B2 (en) * 2004-12-09 2012-04-10 La Jolla Institute For Allergy And Immunology Method for restoring dendritic cell populations
WO2006074399A2 (en) 2005-01-05 2006-07-13 Biogen Idec Ma Inc. Multispecific binding molecules comprising connecting peptides
SG10201804008UA (en) 2005-11-04 2018-06-28 Genentech Inc Use of complement pathway inhibitors to treat ocular diseases
JP2007295524A (ja) * 2006-03-28 2007-11-08 Denso Corp 情報通信システム、施設側装置、ユーザ側装置、管理装置、車両側装置、施設側プログラム、ユーザ側プログラム、管理プログラム及び車両側プログラム
TWI422387B (zh) * 2006-05-25 2014-01-11 Glaxo Group Ltd 免疫球蛋白
US20120282245A1 (en) 2006-10-03 2012-11-08 Biogen Idec Ma Inc. Biomarkers and assays for the treatment of cancer
UA94484C2 (uk) 2006-10-12 2011-05-10 Дженентек, Інк. Антитіла до лімфотоксину-альфа
CN101600450A (zh) * 2006-10-20 2009-12-09 比奥根艾迪克Ma公司 利用可溶性淋巴毒素β受体的脱髓鞘病的治疗
US8338376B2 (en) * 2006-10-20 2012-12-25 Biogen Idec Ma Inc. Compositions comprising variant LT-B-R-IG fusion proteins
TW201716437A (zh) 2006-11-02 2017-05-16 建南德克公司 人類化之抗-因子ｄ抗體及其用途
US8003761B2 (en) * 2007-01-23 2011-08-23 Hoffmann-La Roche Inc. Cancerous disease modifying antibodies
CL2008001071A1 (es) * 2007-04-17 2009-05-22 Smithkline Beecham Corp Metodo para obtener anticuerpo penta-especifico contra il-8/cxcl8, gro-alfa/cxcl1, gro-beta/cxcl2), gro-gama/cxcl3 y ena-78/cxcl5 humanas; anticuerpo penta-especifico; proceso de produccion del mismo; vector, hbridoma o celela que lo comprende; composicion farmceutica; uso para tratar copd, otras enfermedades.
BRPI0813645A2 (pt) 2007-06-25 2014-12-30 Esbatech Alcon Biomed Res Unit Métodos para modificar anticorpos, e anticorpos modificados com propriedades funcionais aperfeiçoadas
CR20170001A (es) 2008-04-28 2017-08-10 Genentech Inc Anticuerpos anti factor d humanizados
TWI513465B (zh) 2009-06-25 2015-12-21 Regeneron Pharma 以ｄｌｌ４拮抗劑與化學治療劑治療癌症之方法
WO2012158818A2 (en) 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
WO2013012733A1 (en) 2011-07-15 2013-01-24 Biogen Idec Ma Inc. Heterodimeric fc regions, binding molecules comprising same, and methods relating thereto
SG11201601044XA (en) 2013-08-12 2016-03-30 Genentech Inc Compositions and method for treating complement-associated conditions
AU2015253042A1 (en) 2014-05-01 2016-10-20 Genentech, Inc. Anti-factor D antibody variants and uses thereof
DK3215528T3 (da) 2014-11-06 2019-10-07 Hoffmann La Roche Fc-regionvarianter med modificeret FcRn-binding og anvendelsesfremgangsmåder
CR20180097A (es) 2015-07-14 2018-05-25 Immunext Inc Anticuerpo anti-cd154 con caracteristicas de unión, funcionalidad y seguridad mejoradas y uso en inmunoterapia humana
EP3368090A1 (en) 2015-10-30 2018-09-05 H. Hoffnabb-La Roche Ag Anti-factor d antibody variant conjugates and uses thereof
US10407510B2 (en) 2015-10-30 2019-09-10 Genentech, Inc. Anti-factor D antibodies and conjugates
EP3430058A4 (en) 2016-03-15 2019-10-23 Generon (Shanghai) Corporation Ltd. MULTISPECIFIC FAB FUSION PROTEINS AND USES THEREOF
EP3847196A4 (en) 2018-09-07 2023-01-04 ITabMed (HK) Limited BISPECIFIC ANTIGEN BINDING PROTEINS AND USES THEREOF
WO2020132810A1 (en) 2018-12-24 2020-07-02 Generon (Shanghai) Corporation Ltd. Multispecific antigen binding proteins capable of binding cd19 and cd3, and use thereof
CA3164226A1 (en) 2019-12-11 2021-06-17 Cilag Gmbh International Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof
JP2024508207A (ja) 2020-12-02 2024-02-26 ブイアイビー ブイゼットダブリュ がんに対する組み合わせ治療におけるｌｔｂｒアゴニスト
WO2022117569A1 (en) 2020-12-02 2022-06-09 Oncurious Nv A ccr8 antagonist antibody in combination with a lymphotoxin beta receptor agonist antibody in therapy against cancer
CN115594759B (zh) * 2021-07-08 2026-04-24 洛阳普泰生物技术有限公司 犬轮状病毒单克隆抗体对及其应用
CR20240246A (es) * 2021-12-20 2024-07-19 Hoffmann La Roche Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden
US20250235534A1 (en) 2022-04-13 2025-07-24 Vib Vzw An LTBR Agonist In Combination Therapy Against Cancer
WO2023218320A1 (en) * 2022-05-11 2023-11-16 Pfizer Inc. Anti-lymphotoxin beta receptor antibodies and methods of use thereof
CN120882754A (zh) 2023-04-07 2025-10-31 瑞泽恩制药公司 用淋巴毒素β受体激动剂治疗癌症的方法
TW202540200A (zh) 2023-12-01 2025-10-16 美商基利科學股份有限公司 抗ｆａｐ－ｌｉｇｈｔ融合蛋白及其用途
WO2025221728A2 (en) 2024-04-15 2025-10-23 Janssen Biotech, Inc. Ltbr binding molecules and uses thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) * 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
JPH06501456A (ja) 1990-06-27 1994-02-17 バイオジェン，インコーポレイテッド 表面複合リンホトキシン
EP0519596B1 (en) 1991-05-17 2005-02-23 Merck & Co. Inc. A method for reducing the immunogenicity of antibody variable domains
WO1994004679A1 (en) * 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
CA2150249A1 (en) 1992-12-04 1994-06-23 Jeffrey Browning Lymphotoxin-.beta., lymphotoxin-.beta. complexes, pharmaceutical preparations and therapeutic uses thereof
US6312691B1 (en) * 1996-01-26 2001-11-06 Jeffrey L. Browning Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents
KR100475492B1 (ko) * 1995-01-26 2005-03-14 바이오겐 아이덱 엠에이 인코포레이티드 항종양제로서의 림프독소-α/β 복합체 및항-림프독소-β수용체 항체
US5925351A (en) * 1995-07-21 1999-07-20 Biogen, Inc. Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease
CA2319698A1 (en) 1998-01-30 1999-08-05 Biogen, Inc. Treatment of follicular lymphomas using inhibitors of the lymphotoxin (lt) pathway
US7060667B1 (en) * 1998-01-30 2006-06-13 Biogen Idec Ma, Inc. Treatment of follicular lymphomas using inhibitors of the LT pathway
GB9809839D0 (en) 1998-05-09 1998-07-08 Glaxo Group Ltd Antibody
CA2491480A1 (en) * 2002-07-01 2004-01-08 Biogen, Inc. Humanized anti-lymphotoxin beta receptor antibodies
WO2004058183A2 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Lymphotoxin beta receptor agents in combination with chemotherapeutic agents
CA2511013A1 (en) * 2002-12-20 2004-07-15 Biogen Idec Ma Inc. Multivalent lymphotoxin beta receptor agonists and therapeutic uses thereof

Also Published As

Publication number Publication date
IS6779A (is) 2003-04-11
US7429644B2 (en) 2008-09-30
AR035352A1 (es) 2004-05-12
YU28503A (sh) 2006-05-25
CN1547590A (zh) 2004-11-17
NO20031642L (no) 2003-06-13
US20040058394A1 (en) 2004-03-25
TR200602095T2 (tr) 2007-02-21
MXPA03003144A (es) 2004-12-06
EE200300179A (et) 2003-08-15
CA2425809A1 (en) 2002-04-18
AU1174702A (en) 2002-04-22
EA006945B1 (ru) 2006-06-30
NZ525793A (en) 2008-04-30
KR20030041164A (ko) 2003-05-23
WO2002030986A2 (en) 2002-04-18
JP2004532608A (ja) 2004-10-28
WO2002030986A3 (en) 2003-03-13
TR200300478T2 (tr) 2004-10-21
BG107802A (bg) 2004-01-30
GEP20063752B (en) 2006-02-27
CZ20031307A3 (cs) 2003-10-15
AU2002211747B2 (en) 2007-11-29
SK5672003A3 (en) 2003-10-07
NO20031642D0 (no) 2003-04-10
IL155340A0 (en) 2003-11-23
EA200300464A1 (ru) 2003-10-30
PL366307A1 (en) 2005-01-24
US20090092601A1 (en) 2009-04-09
EP1326897A2 (en) 2003-07-16
BR0114646A (pt) 2006-02-21

Similar Documents

Publication Publication Date Title
HUP0302573A2 (hu) Humanizált anti-LT-béta-R ellenanyagok
HUP0203567A2 (hu) APRIL-receptor (BCMA) és alkalmazásai
NO20053435L (no) Immunoglobulinvarianter og anvendelser derav
BR0315157A (pt) Métodos de tratar doença de alzheimer empregando-se anticorpos direcionados contra peptìdeo beta amilóide e composições deste
EP1470146B8 (en) Antibodies against the muc18 antigen
MY154009A (en) Anti-alpha v beta 6 antibodies
IL244803A0 (en) Human anti-beta7 antibodies and their use
NO20052512L (no) Purinforbindelser og anvendelse deav som kannabinoiode reseptorligander
NO20034056D0 (no) Proliferative sykdommer
NO20063197L (no) Mutanter av anti-CD40 antistoff
NO20044475L (no) 2-(2,6-diklorfenyl)-diarulimidazoler
PL353750A1 (en) Dosages for treatment with anti-erbb2 antibodies
TW200709817A (en) Platform antibody compositions
NO20055894L (no) Fremgangsmater og blandinger for behandling av amyloidrelatertere sykdommer
DE69934515D1 (de) Humanisierte monoklonale integrin antikörper
EP1583504A4 (en) METHOD AND COMPOSITIONS FOR DIAGNOSIS, FORECAST AND TREATMENT OF CANCER
WO2004031105A3 (en) Use of a33 antigens and jam-it
BR0309095A (pt) Uso de osteoprotegerina para o tratamento e/ou prevenção de doença fibrótica
EP1463527A4 (en) USE OF GAMMAGLOBULIN FOR THE TREATMENT OF IMMUNE-MEDIATED DISEASES
SG149045A1 (en) Novel fused pyrrolocarbazoles
ATE356623T1 (de) 5-ht3-rezeptorantagonisten und verwendungsverfahren
DE60329326D1 (de) Tace inhibitoren
DE60316128D1 (de) N-sulfonylurea-apoptosis-förderer
TR200103448T2 (tr) IL-8 reseptör antagonistleri.
UA86750C2 (ru) Применение il-1f7b, способного связываться с il-18r и il-18bp, вместе с il-18bp для лечения заболеваний, ассоциированных с избыточной активностью il-18

Legal Events

Date Code Title Description
FD9A Lapse of provisional protection due to non-payment of fees